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Today, the Foundation is the world's largest not-for-profit funder of Parkinson's research. It is dedicated to accelerating a cure and improved therapies for the estimated five million people living with Parkinson's disease today. The Foundation pursues its goals through an aggressively funded, highly targeted research program, coupled with the active global engagement of scientists, Parkinson's patients, business leaders, clinical-trial participants, donors, and volunteers.
In addition to funding more than $700,000,000 in research through the end of December 31, 2016, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation (i) forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; (ii) leverages new technologies to amplify the patient voice in Parkinson's research; (iii) mobilizes patients and loved ones to increase the flow of participants into clinical trials; and (iv) coordinates community engagement efforts including patient policy advocacy, education and community building through the grassroots involvement of thousands of Team Fox members around the world.
From inception, the Foundation has invested in high-risk, high-reward research targets -an approach that in a few short years has transformed the field of Parkinson's disease research. The Foundation partners with the Parkinson's research community, speeding financial and intellectual resources to the scientists who are carrying out projects with the greatest promise to impact patients' lives in the near term. This includes strengthening the Parkinson's drug development pipeline by pushing forward investigations of genetic and other disease-modifying targets with the best chance of slowing Parkinson's disease progression, as well as by addressing patients' unmet symptomatic needs. To date, the Foundation has evaluated work on more than 600 therapeutic targets, and is supporting more than 100 clinical trials.
[2] Financial reporting:
(a) Basis of accounting:
The accompanying consolidated financial statements of the Foundation have been prepared using the accrual basis of accounting and conform to accounting principles generally accepted in the United States of America as applicable to not-for-profit organizations.
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Notes to Consolidated Financial Statements December 31, 2016 and 2015 NOTE A -ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
[2] Financial reporting: (continued) (b) Use of estimates:
The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, public support and revenue and expenses, as well as the disclosure of contingent assets and liabilities. Actual results could differ from those estimates.
(c) Cash, cash equivalents, restricted cash, and investments:
For The Foundation maintains a large balance of cash and highly liquid investments in recognition of the fact that a high percentage of these assets have already been committed to future research payments.
(d) Net assets:
The net assets of the Foundation and changes therein are classified and reported as follows:
(i) Unrestricted:
Unrestricted net assets represent those net assets that are not subject to donor restrictions and are available for current operations.
(ii) Temporarily restricted:
Temporarily restricted net assets represent those resources the use of which has been restricted by donors to specific purposes and/or the passage of time. When a donor restriction expires, that is, when a stipulated time restriction ends, or a purpose restriction is accomplished, temporarily restricted net assets are reclassified as unrestricted net assets and are reported in the accompanying consolidated statements of activities as "net assets released from restrictions." A significant value amount of contributions raised from special events are restricted for research. Donated securities are recorded at their fair value at the date of donation. The Foundation's policy is to sell donated securities immediately, and, accordingly, for purposes of the statements of cash flows, donated securities and the proceeds generated from their sale are included as operating activities.
Investment expenses include the services of investment advisors. The balances of investment advisory fees disclosed in Note B are those specific fees charged by the Foundation's investment advisors in each year.
[4] Split-interest agreements:
A portion of the Foundation's assets result from deferred-giving vehicles subject to split-interest agreements. The Foundation currently maintains eight charitable gift annuities.
Charitable gift annuities are unrestricted, irrevocable gifts for which the Foundation agrees in turn to pay a life annuity to the donor or to a designated beneficiary. The contributions and the corresponding liabilities immediately become part of the general assets and liabilities of the Foundation, subject to the Foundation's maintaining an actuarial reserve in accordance with New York State Law.
The Foundation's liabilities associated with the charitable gift annuities are calculated on the basis of actuarial data commonly used by not-for-profit organizations. Discount rates published by the Internal Revenue Service ("IRS") are employed to determine the net present value of both contributions and liabilities pertaining to these deferred-giving arrangements.
[5] Inventory:
The Foundation's inventory consists of merchandise which is valued at the lower of cost or market value, determined on a first-in, first-out method.
[6] Intellectual property:
During 2016, the Foundation established a patent related to a Parkinson's invention. Future revenue from royalties will be recognized as the payments are received. The value of the patent is immaterial to the consolidated financial statements as a whole, and therefore, has not been reported in the accompanying statements of financial position.
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[7] Property and equipment:
Property and equipment are stated at their original costs at dates of acquisition, or, if contributed, at their fair values at the dates of donation. The Foundation capitalizes computer hardware and software, furniture and fixtures, and leasehold improvements with a cost of $2,500 or more, whereas minor costs of repair and maintenance are expensed as incurred. Depreciation of computer hardware and software and furniture and fixtures is provided using the straight-line method over the estimated useful lives of the assets, ranging from three to seven years. Leasehold improvements are amortized over the remaining lease term.
Management evaluates the recoverability of the investment in long-lived assets on an on-going basis and recognizes any impairment in the year of determination. Long-lived assets were tested for impairment as of December 31, 2016 and 2015, respectively, and in the opinion of management, there were no impairments. It is reasonably possible that relevant conditions could change in the near term and necessitate a change in management's estimate of the recoverability of these assets.
[8] Grants payable:
The Foundation records appropriations for research grants as an expense and liability after approval by the Board of Directors, based upon (i) the recommendations of the Research Committee of the Board, with the guidance and input of the Scientific Advisory Board and other highly regarded scientists who serve on grantreview committees specializing in Parkinson's disease research and (ii) the availability of funding. Grants not expected to be paid within the following year are reported at their discounted present values.
[9] Deferred rent:
For financial reporting purposes, the aggregate minimum rent expense is recognized using the straight-line method over the terms of the lease. The accumulative difference between rent expense incurred by the Foundation and the rental amounts paid, which are attributable to scheduled rent increases, is reported as a deferred rent obligation in the accompanying consolidated statements of financial position.
[10] Accrued vacation:
Based on their tenure, the Foundation's employees are entitled to be paid for unused vacation time for a period up to five days, in the event that they leave the Foundation. Accordingly, at each year-end, the Foundation must recognize a liability for the amount that would be incurred if all employees with such unused vacation time were to leave; the obligation is recalculated every year. At December 31, 2016 and 2015, this accrued vacation obligation was approximately $128,000 and $56,000, respectively, and was reported in the accompanying consolidated statements of financial position as a part of accounts payable and accrued expenses.
[11] Revenue recognition:
a. Contributions, grants, and pledges:
Contributions and grants to the Foundation are recognized as revenue upon the receipt of specified cash or other assets or of unconditional pledges and are considered available for unrestricted use, unless specifically restricted on a temporary or permanent basis by the donor. Conditional contributions are recorded when the conditions have been met and, if received in advance, are recognized in the consolidated statements of financial position as deferred revenue. Contributions to be received over periods longer than a single year are discounted at an interest rate commensurate with the risk involved.
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[11] Revenue recognition: (continued)
b. Rental revenue:
Revenue received from the sublease of the Foundation's prior office space is recognized ratably over the length of the term specified in the agreement. Revenue related to rental income received in advance is deferred until the following year.
[12] Advertising costs:
The Foundation expenses the cost of advertising as incurred. Advertising expenses were approximately $1,094,000 and $1,057,000 for 2016 and 2015, respectively.
[13] Volunteers:
A number of unpaid volunteers have made significant contributions of their time performing administrative functions for the Foundation. The value of this contributed time is not recorded in the accompanying consolidated financial statements because it does not meet the criteria for revenue recognition required by generally accepted accounting principles.
[14] Income tax uncertainties:
The Foundation follows the provisions of the Financial Accounting Standards Board's (the "FASB") Accounting Standards Codification ("ASC") Topic 740, Income Taxes, as it relates to accounting and reporting for uncertainty in income taxes. Because the Foundation has always recorded the potential liability for unrelated business income taxes related to its merchandise sales, and due to its general taxexempt status, management believes ASC Topic 740 has not had, and is not expected to have, a material impact on the Foundation's consolidated financial statements.
[15] Subsequent events:
The Foundation considers the accounting treatments, and the related disclosures in the current year's consolidated financial statements, that may be required as the result of all events or transactions that have occurred after December 31, 2016 through May 9, 2017, the date on which the financial statements were available to be issued.
[16] Reclassification:
Certain information in the prior year's consolidated financial statements has been reclassified to conform to the current year's presentation.
[17] Recent accounting pronouncement:
In August 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-14, Presentation of Financial Statements of Not-for-Profit Entities. ASU 2016-14 will amend financial-statement presentations and disclosures, with the goal of assisting not-for-profit organizations in providing more relevant information about their resources (and the changes in those resources) to donors, grantors, creditors, and other users. ASU 2016-14 includes qualitative and quantitative requirements in the following areas: (i) net asset classifications, (ii) investment returns, (iii) expense categorizations, (iv) liquidity and the availability of resources, and (v) the presentation of operating cash flows. The new standard is effective for annual reporting periods beginning after December 15, 2017. The Foundation will adopt ASU 2016-14 when it becomes effective. 
NOTE B -INVESTMENTS (CONTINUED)
The availability of market data is monitored by the Foundation's management, to assess the appropriate classification of financial instruments within the fair-value hierarchy. Changes in economic conditions or valuation techniques may require the transfer of financial instruments from one level to another. In such instances, the transfer is reported at the beginning of the reporting period. During 2016 and 2015, there were no transfers among the fair-value hierarchy levels.
The following is a summary of the fair values of investments and other applicable assets at each year-end, in accordance with these fair-value levels: 
NOTE F -LOANS PAYABLE
In 2008, the Foundation entered into a loan agreement with a bank, the terms of which stipulate that the Foundation record the present value of $2,450,000, discounted at a rate of 4.53% per annum. Interest is compounded on a semiannual basis, and no principal or interest payments are due until 2028.
During 2012, the Foundation entered into an additional loan agreement with the bank, the terms of which stipulate that the Foundation must record the loan's present value of $228,600, discounted at a rate of 2.56% per annum.
Interest is compounded on a semiannual basis, and no principal or interest payments are due until 2028.
The loan balances, net of original issue discounts, were $1,150,196 as of both December 31, 2016 and 2015, respectively, and accrued interest payable as of December 31, 2016 and 2015 was $469,706 and $401,917, respectively. Funds obtained were applied to fund research focused on developing a cure for Parkinson's disease.
NOTE G -TEMPORARILY RESTRICTED NET ASSETS
At each year-end, temporarily restricted net assets were restricted for the following: 
